Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Morphosys Ag ADR (MOR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,346,029
  • Shares Outstanding, K 125,980
  • Annual Sales, $ 75,490 K
  • Annual Income, $ -78,920 K
  • 36-Month Beta N/A
  • Price/Sales 30.33
  • Price/Cash Flow N/A
  • Price/Book 5.46

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.30
  • Number of Estimates 2
  • High Estimate -0.28
  • Low Estimate -0.31
  • Prior Year -0.15
  • Growth Rate Est. (year over year) -100.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
24.24 +9.12%
on 01/30/19
29.94 -11.66%
on 01/25/19
-2.30 (-8.00%)
since 01/18/19
3-Month
24.24 +9.12%
on 01/30/19
30.08 -12.07%
on 12/03/18
-0.23 (-0.86%)
since 11/21/18

Most Recent Stories

More News
MorphoSys to Present at Upcoming Investor Conference

PLANEGG and MUNICH, GERMANY / ACCESSWIRE / February 21, 2019 / MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) will present at the following conference:

MOR : 26.45 (-0.41%)
Simon Moroney, CEO and Co-Founder of MorphoSys, Announces His Intention to Retire

PLANEGG and MUNICH, GERMANY / ACCESSWIRE / February 19, 2019 / Simon Moroney, CEO and co-founder of MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX & MDAX; NASDAQ: MOR), informed the Company's Supervisory...

MOR : 26.45 (-0.41%)
Ad hoc: Simon Moroney, CEO and Co-Founder of MorphoSys, Announces His Intention to Retire

PLANEGG and MUNICH, GERMANY / ACCESSWIRE / February 19, 2019 / Simon Moroney, CEO and co-founder of MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX & MDAX; NASDAQ: MOR), informed the Company's Supervisory...

MOR : 26.45 (-0.41%)
MorphoSys Announces Settlement in Patent Lawsuit with Janssen and Genmab

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / January 31, 2019 / MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) announced today that in its lawsuit against Janssen Biotech and Genmab...

MOR : 26.45 (-0.41%)
GNMSF : 163.9176 (+2.36%)
MorphoSys Announces that its Licensee Janssen has Expanded Clinical Development of Guselkumab (Tremfya(R)) into Ulcerative Colitis

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / January 17, 2019 / MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) announced today that its licensee Janssen Research & Development, LLC...

MOR : 26.45 (-0.41%)
MPSYY : 27.9300 (+0.87%)
MPSYF : 107.9500 (-1.05%)
MorphoSys AG: Corporate Calendar 2019

MorphoSys (FSE: MOR; NASDAQ: MOR)

MOR : 26.45 (-0.41%)
MorphoSys's Licensee Janssen Announces Data from the Phase 3 Head-to-Head Study ECLIPSE Demonstrating Superiority of Tremfya(R) vs. Cosentyx(R) as Measured by PASI 90 at Week 48 in the Treatment of Plaque Psoriasis

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / December 12, 2018 / MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) reported today that its licensee Janssen has announced that results...

MOR : 26.45 (-0.41%)
Griffon Pharmaceuticals appoints Dr. Marc Cluzel to Board of Directors

Montreal-based biopharmaceutical company Griffon Pharmaceuticals Inc. ("Griffon") announced today that Marc Cluzel, MD, PhD, joins the company's Board of Directors.

MOR : 26.45 (-0.41%)
BK Technologies Declares Quarterly Dividend of $0.02 per Share

WEST MELBOURNE, FL / ACCESSWIRE / December 7, 2018 / BK Technologies, Inc. (NYSE: BKTI) today announced that today its Board of Directors declared a quarterly dividend of $0.02 per share of the Company's...

IIPR : 68.60 (+5.67%)
AAPL : 171.06 (-0.56%)
TX : 29.85 (+0.88%)
EFR.TO : 4.02 (+1.52%)
CIIX : 0.4600 (-4.17%)
ITRO : 0.9784 (+2.99%)
CNDGF : 0.4300 (+43.33%)
ZC.VN : 0.275 (+1.85%)
PKTEF : 0.2140 (-2.73%)
CRON : 22.47 (+1.08%)
VFC : 85.80 (-0.66%)
ACBFF : 8.6900 (-12.80%)
CVSI : 4.8305 (-2.41%)
COUP : 92.28 (-1.64%)
Y.TO : 5.93 (-2.47%)
GRUB : 79.50 (-2.67%)
MDR : 7.59 (-1.81%)
ESK.VN : 0.075 (unch)
EA : 96.86 (-1.79%)
CLSK : 5.6800 (+15.92%)
BABA : 171.66 (+0.56%)
MO : 50.37 (-0.28%)
XXMMF : 0.4274 (-1.04%)
AEM : 43.37 (-0.85%)
SING : 0.0188 (-0.53%)
EW : 173.94 (-1.55%)
DATA : 130.40 (+2.64%)
EIX : 61.26 (-2.27%)
XIM.VN : 0.620 (+5.08%)
ATVI : 41.90 (-2.06%)
HTHT : 34.34 (-2.94%)
SSRM : 14.13 (+1.58%)
JRSH : 6.38 (-1.54%)
ZTMUF : 0.1904 (+7.57%)
MAR : 127.37 (+0.32%)
EXE.TO : 7.52 (unch)
GBT.TO : 15.22 (-0.07%)
NBEV : 6.31 (-0.94%)
AVGO : 280.94 (-0.88%)
ORRP : 0.2010 (-6.51%)
DIIBF : 12.6900 (+1.34%)
FDIT : 0.0482 (-3.21%)
CMCM : 7.18 (+0.14%)
KLGDF : 10.5858 (+1.11%)
SHOP : 178.47 (-0.41%)
ESKYF : 0.0610 (-0.81%)
APOG : 37.10 (+0.41%)
SIA.TO : 17.80 (-0.78%)
TSRO : 74.96 (+0.03%)
GE : 10.03 (-0.69%)
NKTR : 40.26 (-6.44%)
ACB : 7.06 (-0.14%)
TWLO : 113.16 (-2.70%)
BKTI : 4.17 (+4.25%)
GLUU : 9.10 (-0.66%)
KR : 28.58 (-0.59%)
MGI : 2.48 (-0.80%)
MKL : 1,010.40 (-0.92%)
MOR : 26.45 (-0.41%)
OCLN : 0.0018 (unch)
IDTI : 48.54 (-0.06%)
AMRN : 17.43 (+1.34%)
APHA : 10.38 (+2.27%)
APTI : 37.97 (-0.03%)
L.TO : 65.50 (-1.56%)
MorphoSys Presents Updated Data from L-MIND Study of MOR208 plus Lenalidomide in r/r DLBCL at ASH 2018

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / December 1, 2018 / MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) today presented data from the ongoing single-arm phase 2 clinical trial...

MOR : 26.45 (-0.41%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More Share

Trade MOR with:

Business Summary

MorphoSys AG is a biopharmaceutical company. It develops treatment for cancer, inflammations and autoimmune diseases. The company's proprietary portfolio consists of MOR208, MOR202, MOR103, MOR106 and MOR107. Its partnered programs lighthouse project includes Tremfya(R) and Gantenerumab. MorphoSys AG...

See More

Key Turning Points

2nd Resistance Point 26.82
1st Resistance Point 26.64
Last Price 26.45
1st Support Level 26.21
2nd Support Level 25.96

See More

52-Week High 35.90
Fibonacci 61.8% 30.49
Fibonacci 50% 28.83
Fibonacci 38.2% 27.16
Last Price 26.45
52-Week Low 21.75

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar